GOA Therapeutics Filed SEC Offering Statement
The company seeks to raise $75 million through a new Regulation A stock offering.
Updated on Sept. 30, 2026 in Public Companies
Live Poll
Is now a good time for you to invest in speculative biotechnology public offerings?
West Palm Beach-based GOA Therapeutics has filed an offering statement with the SEC for a proposed Regulation A public offering. The company is offering up to 5 million shares of common stock at $15.00 per share.
Why it matters
The company intends to use the proceeds to fund the clinical development, manufacturing, and commercialization planning of its investigational candidate, GOA26. This candidate is designed to treat acute alcohol intoxication.
The proposed Regulation A offering consists of 5 million shares at $15.00 per share, totaling $75 million. This is part of a broader strategy contemplating aggregate offerings of up to $300 million.
The players
GOA Therapeutics
A West Palm Beach-based biotechnology company developing treatments for acute alcohol intoxication.
DealMaker Securities LLC
The broker-dealer firm engaged to manage the Regulation A offering process for GOA Therapeutics.
The details
GOA Therapeutics engaged DealMaker Securities LLC as the broker-dealer for this offering. In preclinical porcine studies, the firm's drug candidate, GOA26, successfully reduced blood alcohol concentrations by 61.3% within 20 minutes.
Timeline
September 30, 2026: GOA Therapeutics filed its offering statement on Form 1-A with the SEC.
Market Landscape
This move marks a significant capital-raising milestone for the company within the biotech sector, where firms often utilize Regulation A offerings to fund extended clinical trial phases. The strategy positions GOA Therapeutics to bridge the gap between preclinical results and human clinical trials.
While this filing primarily impacts institutional and retail investors interested in the biotechnology sector, it does not currently change product pricing or service availability for the average consumer. Investors should monitor future announcements regarding the formal launch of the offering.
The takeaway
The move demonstrates how emerging biotech firms leverage specialized SEC filing pathways to move experimental drugs closer to clinical validation. Investors often watch these filings as early indicators of a company's transition from research-only to development-stage operations.
Further reading
For more information on the local business environment, visit the Public Companies section.
More information
Access the full SEC preliminary offering circular for comprehensive details on the filing.
Live Poll
Is now a good time for you to invest in speculative biotechnology public offerings?
